leisure time -WSS

leisure time

author：hotspot 2025-09-03 11:47:05 - browse：79433

A medical insurance document printed with the words "COPAY," "DEDUCTIBLE," "COINSURANCE," "NON-COVERED," next to a pen — coverage from STAT — Adobe

WASHINGTON — Insurers will have to count drug copay coupons toward deductibles and patient spending caps in most cases, after a Biden move in federal court on Tuesday.

Drug companies use copay coupons to help patients cover the cost of their drugs.

Before now, when drug companies helped patients pay their share of drug costs, insurers often didn’t count that assistance toward deductibles and out-of-pocket limits. In insurance jargon, this tactic is called a copay accumulator. Previously, the practice was only allowed when drug companies give coinsurance assistance for brand drugs with generic competition. The Trump administration let insurers use the tactic when cheaper generics were not available.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Medicare to cover more brain scans related to Alzheimer’s drugs

WSS

Biotech lab space demand falls sharply

Researchers CRISPR chickens in bid to protect them from bird flu

Drug for rare kidney disease narrowly misses mark in clinical trial

How doctors and nurses shape Google's AI

Wellcome Trust names Røttingen as its new CEO

A revolution in caring for preterm infants

hotspot

leisure time

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Readout: Today's biotech news includes Sana and Amylyx

Duchenne breakthrough therapy leaves behind pioneering families

What's changing in Medicare's open enrollment this year?

Jerome Adams on the need for new antivirals for Covid

Senators: Long

As demand for Covid shots wanes, Moderna seeks its next success

Microbiome research is starting to find links to chronic diseases

Hepatitis C has a cure — but many Americans still lack access to it

Changes to biosimilar regulatory framework must prioritize patients

Wikipedia

Takeaways from AdvaMed, the largest medical devices conference

Thermo Fisher plant for manufacturing gene therapies to expand

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Biotech lab space demand falls sharply

How should state employee insurance handle Wegovy?

CommonSpirit Health keeps growing, even as it loses money

explore

hotspot

hotspot

hotspot